Physician profile
Don W Lee
NPI 1104806421
$27,949.48
in general payments reported to CMS, 2019-2025
45 companies · $869 in 2025
The $869 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,763 · 2020: $6,366 · 2021: $3,775 · 2022: $3,520 · 2023: $2,875 · 2024: $2,781 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,391 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,391.35 |
| Education | $134.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $9,098.33 | 2019-2025 | Auryon Laser System 100-120 Vac |
| Novartis Pharmaceuticals Corporation | $2,375.86 | 2019-2025 | |
| Amgen INC. | $1,862.64 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,819.27 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $1,203.69 | 2020-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,105.71 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $969.94 | 2019-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $859.69 | 2019-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $838.69 | 2019-2023 | Livalo |
| E.R. Squibb & Sons, L.L.C. | $830.91 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $738.61 | 2021-2025 | Verquvo, Winrevair |
| Lexicon Pharmaceuticals, INC. | $664.03 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $627.82 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $620.25 | 2019-2025 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $591.09 | 2019-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.